Important risk disclosure

Please click here and read carefully the summary of the key features and risks specific to this fund stated in the offering document prepared by the relevant fund house before making any investment decision.

You should not rely solely on the information contained on this webpage to make investment decisions. You should read carefully and understand the relevant fund's offering documents before making any investment decision.

LU0133096635
T. Rowe Price Funds SICAV - US Smaller Companies Equity Fund

  • Equities
  • US
  • USD Cash
  • Accumulating
Invest with
USD Cash
Payout type
Accumulating
Risk rating
6
About this fund
Description
The Fund seeks to increase the value of its shares, over the long term, through growth in the value of its investments.
Key information
Annual report
Key fact sheet
Prospectus
Factsheet
Our perspective
Why we think this fund is best-in-class
product
Product
Long standing US Small and mid cap strategy (launched in 2001) that is style neutral with broad exposure to both growth and value small and mid-cap companies.
Read more
people
People
Portfolio Managers Curt Organt and Matt Mahon collectively have more than 40 years of experience. They are supported by the broader equity research team of more than 50 analysts. Receive significant support from the broader team of T.Rowe Price portfolio managers and analysts, who advise and suggest candidates for the portfolios. Large analyst pool is crucial for small cap investing as it is an inefficient space and understanding both the opportunities and the risks associated with smaller companies is key to identifying the winners T. Rowe Price, as a firm, is one of the pioneers in small cap investing with more than 70bn USD in AUM in small cap funds. T. rowe has been managing US small cap strategies since 1960.
Read more
performance
Performance
The strategy was launched in 2001 and has outperformed its benchmark since inception with stock selection driving the outperformance. Downside capture has been very strong, losing less than the market and this has allowed the strategy to generate strong returns across all market cycles; lower downside capture has helped the fund to compound its returns over the long term.
Read more
process
Process
Bottom up process with a focus on free cash flow metrics, as the team believes FCF to be the purest measure of corporate financial performance and is central to determining value in the small and mid-cap market. Ideal candidates are companies below 18bn in market capitalisation with durable competitive advantages and a strong management team capable of adding value through the cycle. Resulting portfolio is between 150 to 200 holdings with broad exposure to both growth and value stocks that are within the market capitalization range of the Russell 2500 Index at time of purchase.
Read more
cost
Cost
Access to the retail share class with 100% trailer fee rebated back to Endowus investors to achieve a lower cost of access.
Read more
selectionCriteria
How it fits in a portfolio
Investors looking for exposure to smaller US companies can consider the Fund as a satellite exposure to complement their core equity holding. While the Fund is diversified with 150-200 holdings and a small average holding size , it focuses on smaller companies that are typically more volatile in nature. Therefore, investors should be mindful of the risk involved, although the Fund's performance has shown that investors have historically been rewarded for taking such risks. This Fund is also country specific and investors should ensure that they construct their portfolio to build more diversity and avoid concentration risks.
Read more
Invest in this fund
Performance
Shows the total return of this accumulating fund, which includes dividends reinvested.
Total returns
All Time
419.71%
YTD
1.97%
1 month
2.45%
6 month
4.66%
1 year
2.78%
3 year
26.61%
5 year
45.79%
10 year
171.05%
As of Aug 2025
Distributions
This is an accumulating fund, so dividends are re-invested at the fund level.
Risk metrics
Max drawdown
-50.03%As of Aug 2025
Volatility
18.02%As of Aug 2025
Calendar returns
YearTotalJanFebMarAprMayJunJulAugSepOctNovDec
2025-2.8%-5.2%-6.0%-4.4%6.8%4.7%1.7%2.4%----
20246.3%-0.9%2.8%3.3%-5.3%1.7%-0.8%5.6%-0.7%1.4%-0.7%8.4%-7.7%
202322.5%7.8%0.4%-3.6%-0.2%-0.5%7.5%3.7%-1.9%-4.4%-6.4%10.0%9.8%
2022-21.1%-10.6%1.2%2.9%-6.1%-3.9%-8.7%10.4%-2.1%-8.6%7.0%0.7%-3.1%
202115.9%2.4%4.0%1.2%5.0%-2.0%0.8%0.8%1.5%-1.6%4.2%-3.4%2.4%
Load more5 of 20
Top Exposures
PTC Inc2.47%
APi Group Corp2.20%
Elanco Animal Health Inc1.95%
Haemonetics Corp1.88%
Teledyne Technologies Inc1.75%
Regions Financial Corp1.58%
Parsons Corp1.57%
Revvity Inc1.54%
Atmos Energy Corp1.48%
OGE Energy Corp1.37%
Frontdoor Inc1.29%
Vontier Corp Ordinary Shares1.26%
Silgan Holdings Inc1.24%
Ingersoll Rand Inc1.22%
CubeSmart1.15%
Top exposures represent up to 15 of the fund's largest exposures for each category. Allocation percentages may not sum up to 100% and can include negative values due to rounding or trading activities by the underlying fund managers, including short positions.
Fund fees
1.70%0.82% p.a.
Save 51%
Fund facts
ISIN
LU0133096635
Fund house
T. Rowe Price
Fund size
US$3.3B
As of 09 Sep 2025
Fund inception date
31 Jul 2001
Fund class currency
USD
Fund share class
A USD
Oldest share inception date
31 Jul 2001
Pricing frequency
Daily

Warning statements

  • All investments involve risks (including the possibility of loss of the capital invested) and the price of fund units may go up as well as down.
  • Past performance is not indicative of future performance.
  • Although this fund has been authorised by the Hong Kong Securities and Futures Commission (“SFC”), it does not imply an official recommendation or endorsement by the SFC nor does it guarantee the commercial merits of the fund or its performance.
  • If you are in any doubt, you should clarify with us or seek independent professional advice.

Risk Warnings Investment involves risk. Past performance is not an indicator nor a guarantee of future performance or returns. Projected performance or returns are not guaranteed to materialise. The value of investments and the income from them can go down as well as up, and you may not get the full amount you invested. Rates of exchange may cause the value of investments to go up or down. Individual stock performance does not represent the return of a fund.

The value of the fund can be volatile and can go down substantially within a short period of time. It is possible that a certain amount or all of your investment could be lost.

Generic risk warnings relating to collective investment schemes

Funds are not a bank deposit and not capital guaranteed, and is subject to investment risks, including the possible loss of the principal amount invested. There is no assurance that a fund will have sufficient liquidity to meet redemption requests and that the fund's investment objectives and strategies will be achieved.

The funds' investment may involve substantial market, currency, volatility, liquidity, regulatory and political risks. Some funds may use derivatives, whether for hedging or for investment purposes. The risks associated with derivatives include counterparty/credit, liquidity, valuation, volatility and market risks. The fund's volatility may increase or decrease from its derivative usage and such fund may suffer losses from its derivative usage. Do not invest in these funds unless you fully understand and are willing to assume the risks associated with them.

Opinions Any forward-looking statements, prediction, projection or forecast on the economy, stock market, bond market or economic trends of the markets contained in this material are subject to market influences and contingent upon matters outside the control of Endowus HK Limited (“Endowus”) and therefore may not be realised in the future. Further, any opinion or estimate is made on a general basis and subject to change without notice. In presenting the information above, none of Endowus HK Limited, its affiliates, directors, employees, representatives or agents have given any consideration to, nor have made any investigation of the objective, financial situation or particular need of any user, reader, any specific person or group of persons. Therefore, no representation is made as to the completeness and adequacy of the information to make an informed decision. You should carefully consider (i) whether any investment views and products/ services are appropriate in view of your investment experience, objectives, financial resources and relevant circumstances. You may also wish to seek financial advice through a financial advisor or the Endowus platform and independent legal, accounting, regulatory or tax advice, as appropriate.

Third party content ©2025 Morningstar. All Rights Reserved. The information contained here relating to a particular collective investment scheme: (1) is proprietary to Morningstar Research Pte. Limited and/or its content providers (“Information Provider(s)“) unless otherwise specified; and (2) may not be copied or distributed. Neither the Information Provider nor Endowus guarantee or endorse the accuracy, reliability, completeness or timeliness of the information, or are responsible for any damages or losses arising from any use of this information. Further, for technical reasons, certain information provided by Information Provider may be different from that supplied by the respective fund houses.

No invitation or solicitation Nothing contained on this webpage should be construed as a solicitation, recommendation or an offer by Endowus or any of its affiliates to buy or sale any security, commodity, investment or to engage in any other transaction in any jurisdiction in which such solicitation, recommendation or offer to buy or sale would be unlawful under the securities laws in such jurisdiction. No information included on this webpage is to be construed as investment advice or as a recommendation or a representation about the suitability or appropriateness of any advisory product or service; or an offer to buy or sell, or the solicitation of an offer to buy or sell, any security, financial product, or instrument; or to participate in any particular trading strategy. Investors should seek independent financial and tax advice before making any investment decision.

Product Risk Rating Please note that any product risk rating (the “PRR”) provided by us is an internal rating assigned based on our product risk assessment model, and is for your reference only. The PRR is subject to change from time to time. The PRR does not take into account your individual circumstances, objectives or needs and should not be regarded as advice or recommendation to purchase, hold or sell any fund or make any other investment decisions. Accordingly, you should not solely rely on the PRR in making your investment decision in the relevant Fund.

The contents of this webpage have not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.

Disclaimer:

General This website has been prepared by Endowus HK Limited ("Endowus"), which is licensed (CE No. BQR225) by the Securities and Futures Commission (the "SFC") in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) to carry on business in Type 1 (Dealing in Securities), Type 4 (Advising on Securities) and Type 9 (Asset Management) regulated activities. You can verify this information on the SFC's website here.

Jurisdictional Disclaimers By accessing this website, you acknowledge that you are a resident of Hong Kong. This website is not intended for U.S. Persons and should not be accessed by persons located or resident any other jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local laws or regulations or would subject Endowus to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licences, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your access to this website.

The content contained in this website has not been reviewed by the SFC or any regulatory authority in Hong Kong and are subject to the Privacy Policy and the full disclaimer found here.